Hormone-refractory metastatic prostatic cancer treated with methotrexate, cyclophosphamide plus adriamycin, cis-platinum plus 5-fluorouracil plus cyclophosphamide National prostatic cancer project randomized trial

Urology

Volumn 32, Issue 1, 1988, Pages 33-40

  Murphy, G P ^a,b   Priore, R L ^a,b   Scardino, P T ^a,b   Investigators of National Prostatic Cancer Project, ^c  

^a UNIVERSITY AT BUFFALO   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; METHOTREXATE;

ANOREXIA; BLOOD TOXICITY; EDEMA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROSTATE CARCINOMA; SKIN TOXICITY; SURVIVAL;

ACID PHOSPHATASE; ALKALINE PHOSPHATASE; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; CLINICAL TRIALS; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; HUMAN; MALE; METHOTREXATE; PROSTATIC NEOPLASMS; RANDOM ALLOCATION; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0023773046     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/0090-4295(88)90450-5     Document Type: Article

References (24)

1. A decade of experience with chemotherapy for prostate cancer
2. Participants in the National Prostatic Cancer Project: Criteria for evaluating patient responses to treatment modalities for prostatic cancer
3. The continued evaluation of the effect of chemotherapy in patients with advanced carcinoma of the prostate
4. A comparison of hydroxyurea methotrexate and cyclophosphamide in patients with advanced carcinoma of the prostate
5. Comparison of estramustine phosphate, methotrexate and cis-platinum in patients with advanced hormone refractory prostate cancer
6. Comparison of Adriamycin (adria) and 5-fluorouracil (5-FU) in advanced prostate cancer
7. Comparison of Adriamycin (NSC-123127) and the combination of 5-fluorouracil (NSC-19893) and cyclophosphamide (NSC-026271) in advanced prostate cancer: a preliminary report
8. Cytoxan, Adriamycin and methotrexate (CAM) therapy of stage D prostate cancer
9. Adriamycin (ADM) and diamminedichloroplatinum (DDP) in advanced prostatic carcinoma (PC)
10. Effective treatment of hormonallyunresponsive metastatic carcinoma of the prostate with Adriamycin and cyclophosphamide
11. The treatment of estrogenresistant Stage D carcinoma of the prostate with cisdiamminedichloroplatinum
12. Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate?
13. A re-evaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostate carcinoma
14. The chemotherapy of prostatic adenocarcinoma
15. Regression models and life-tables (with discussion)
16. An analysis of the effects of changes from the assigned treatment in a clinical trial of treatment for prostatic cancer
17. The natural history of prostate carcinoma
18. Carcinoma of the prostate
19. Treatment of stage IV carcinoma of the prostate
20. Non-hormonal cytotoxic agents in the treatment of prostatic adenocarcinoma
21. Multiple drug chemotherapy regimen for patients with hormonally-unresponsive carcinoma of the prostate: a preliminary report
22. Chemotherapy of prostatic cancer
23. the Investigators of the National Prostatic Cancer Project: Prognostic factors in patients with advanced stage prostate cancer